Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 evaluation of clascoterone cream for adrenal suppression and pharmacokinetics in acne vulgaris
2023-000462-33Phase 2
- Sponsor
- Intrepid Therapeutics, Inc.
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clascoterone in acne vulgaris, sponsored by Intrepid Therapeutics, Inc. Primary endpoints: HPA Axis Response to Cosyntropin and Pharmacokinetic properties of clascoterone.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2023-000462-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000462-33.